摘要
目的:探讨N-乙酰化转移酶2(NAT2)基因在结肠癌组织中的表达及其与预后的相关性。方法:下载公共数据库中(Oncomine和TCGA)有关NAT2基因表达的数据集,利用在线平台进行数据挖掘,然后对NAT2在结肠癌中的作用进行荟萃分析。结果:Oncomine中检索到涉及NAT2基因的研究包含结肠癌446例和正常组织200例,TCGA中检索到涉及NAT2基因的研究包含结肠癌286例和正常组织41例。与正常结肠组织相比,在结肠癌中NAT2 mRNA的表达量显著降低(P<0.01)。另外,免疫组化结果表明NAT2在正常组织中呈较强或中等表达,而在结肠癌组织中则表达较弱或呈阴性。通过分析结肠癌患者的生存信息发现,NAT2基因低表达患者有着更高的死亡率,而高表达NAT2的患者则预后较好(P<0.05)。结论:在结肠癌中,NAT2基因和蛋白均呈现低表达,并与结肠癌预后相关,有望发展为结肠癌新的诊断和治疗靶点。
Objective:To investigate the expression,clinical and prognostic significance of N-acetyltransferase 2(NAT2)gene in colorectal cancer.Methods:Datasets related to NAT2 gene expression in Oncomine and TCGA databases were extracted by data mining,and then the role of NAT2 in colorectal/colon cancer was meta-analyzed.Results:The study involving NAT2 gene in Oncomine included 446 cases of colon cancer and 200 cases of normal tissues,and the study involving NAT2 gene in TCGA included 286 colon cancer and 41 normal tissue cases.Compared with normal colon tissue,the expression of NAT2 mRNA in colon cancer was significantly lower than that in normal colon tissue(P<0.01).In addition,immunohistochemistry showed that NAT2 was strongly or moderately expressed in normal tissues,but weakly or negatively expressed in colon cancer tissues.Compared with normal colon tissue,the expression of NAT2 protein in colon cancer was significantly lower than that in normal colon tissue(P<0.01).Moreover,it was found that patients with low NAT2 expression had a higher overall mortality,while patients with high NAT2 expression had a better prognosis by mining the UALCAN and GEPIA database(P<0.05).Conclusion:The mRNA and protein of NAT2 are lower expressed in colon cancer tissues and are related to the prognosis of colon cancer,which is expected to be a new therapeutic target for colon cancer.
作者
余涛
李丹
王文龙
吴杰
宋伟
YU Tao;LI Dan;WANG Wenlong;WU Jie;SONG Wei(Integrated Traditional Chinese and Western Medicine Ward of Oncology Department,the Central Hospital of Wuhan,Tongji Medical College,Huazhong University of Science&Techonology,Hubei Wuhan 430014,China;Department of Pharmacy,Renmin Hospital of Wuhan University,Hubei Wuhan 430060,China;Intensive Care Unit,Hangzhou Hospital of Traditional Chinese Medicine,Zhejiang Hangzhou 310007,China)
出处
《现代肿瘤医学》
CAS
北大核心
2021年第15期2657-2661,共5页
Journal of Modern Oncology
基金
国家自然科学基金项目(编号:81803789,81704023)
吴阶平医学基金会(编号:320.6750)
武汉大学人民医院引导基金(编号:RMYD2018M79)。
